Summit Therapeutics Inc
SMMT - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$12.79B
Close$
Earnings Call Q1 2025
May 2, 2025 - AI Summary
Regulatory Milestones and Clinical Developments: Summit Therapeutics' partner Akeso has received approval for ivonescimab as a frontline monotherapy treatment for non-small cell lung cancer (NSCLC) in China, marking a significant regulatory achievement. The therapy demonstrated a 39% positive trend in overall survival during an interim analysis compared to pembrolizumab, indicating ivonescimab's potential to improve patient outcomes and solidify its competitive position.
Upcoming Clinical Data and Expectations: The HARMONi global Phase III trial, targeting EGFR mutated advanced NSCLC after third-generation tyrosine kinase inhibitor treatment, is expected to report top line data in mid-2025. This data will assess both progression-free survival and overall survival, crucial in evaluating ivonescimab's efficacy and establishing its market potential in Western regions, especially against existing therapies that have been unsuccessful in this setting.
Commercial Strategy and Team Expansion: Summit has strengthened its commercial capabilities by appointing Robert LaCaze as Chief Commercial Officer, with experience in launching and managing oncology products. This indicates the company’s preparation for a potential market launch of ivonescimab and aims to optimize penetration in the multi-billion dollar NSCLC market.
Exclusive for Stockcircle Pro members
Sign up
$0.27
98.3% downside
Current Fair Value
98.3% downsideOvervalued by 98.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $12.79 Billion |
|---|---|
| Enterprise Value | $12.39 Billion |
| Earnings per Share | $-1.44 |
| Beta | -1.24 |
| Outstanding Shares | 778,184,568 |
Return
| Return on Equity | -135.89% |
|---|---|
| Return on Assets | -113.81% |
| Return on Invested Capital | -59.87% |
Valuation & Multiples
| P/E Ratio | -14.31 |
|---|---|
| PEG | 23.13 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -31.91 |
| Enterprise Value to Net Income | -15 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 2, 2026
EPS Estimate
$-0.28
Consensus analyst estimateRevenue Estimate
$72,125
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 86.80% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.24%▼ 17.41% |
|---|---|
| Total Invested | $31.49M▼ 98.42% |
| Investors Holding | 59▼ 210.00% |